Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 837

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 837
---
 both basic and diluted net loss per share attributable to common stockholders is the same. For the years ended December 31, 2024 and 2023, the Company excluded the following potential common shares from the computation of diluted net loss per share attributable to common stockholders for the period because including them would have had an anti-dilutive effect:

|                                      |     | As of December 31, |            |     |      |            |
|                                      |     |               2024 |            |     | 2023 |            |
| Preferred Series A (as converted)    |     |                    |          — |     |      |  7,053,338 |
| Preferred SeriesA-1(as converted)    |     |                    |          — |     |      |  4,500,142 |
| Preferred Series B (as converted)    |     |                    |          — |     |      |  5,359,363 |
| Convertible Notes (as converted)     |     |                    |          — |     |      |    847,670 |
| Stock options issued and outstanding |     |                    |  6,403,818 |     |      |  2,781,064 |
| Unvested restricted stock units      |     |                    |        114 |     |      |          — |
| Warrants                             |     |                    | 10,609,855 |     |      |  8,083,775 |
| Total                                |     |                    | 17,013,787 |     |      | 28,625,352 |

F-81

TUHURA BIOSCIENCES, INC AND SUBSIDIARIES Notes to the consolidated financial statements For the years ended December 31, 2024, and 2023

Note 5-Fairvalue measurements

The following tables present information about financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values:

|                      |     | December 31, 2023 |   |     |         |   |     |         |         |     |       |         |
|:---------------------|:----|:------------------|:--|:----|:--------|:--|:----|:--------|--------:|:----|:------|--------:|
|                      |     | Level 1           |   |     | Level 2 |